Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8475524 | 0.84 | HMGCR (0.43) | TAAR1PTGS2ALDH1A1 | |
| SCHEMBL457842 | 0.83 | TAAR1 (0.37) | TAAR1L3MBTL1KDM4EPTGS2TSHR | |
| SCHEMBL2480627 | 0.82 | PDE4A (0.44) | MAPTCA12CA1CA2CA4 | |
| SCHEMBL9409469 | 0.82 | TAAR1 (0.37) | TAAR1KDM4EMAPTATMCA12 | |
| SCHEMBL6436641 | 0.82 | MCL1 (0.33) | CA12CA1CA2CA4CA7 | |
| SCHEMBL7448619 | 0.82 | L3MBTL1 (0.47) | L3MBTL1KDM4EMAPTHPGDNPSR1 | |
| SCHEMBL6203846 | 0.82 | IDO1 (0.37) | CA12CA1CA2CA4CA7 | |
| SCHEMBL4409587 | 0.81 | ALOX5 (0.42) | PTGS2 | |
| SCHEMBL18705900 | 0.80 | SLC6A4 (0.42) | MAPTGAAALDH1A1 | |
| SCHEMBL58401 | 0.80 | GABRA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4673977-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| EP-1165085-B1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2006-06-14 | — | — | EP | claimed |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2005-08-11 | — | — | US | claimed |
| US-6911440-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2005-06-28 | — | — | US | claimed |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | BOLD GUIDO (CH) | 2004-07-22 | — | — | US | claimed |
| US-6686347-B2 | RHEUMATIC DISEASES; ANALGESICS; ENZYME INHIBITORS | NOVARTIS AG (CH) | 2004-02-03 | — | — | US | claimed |
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2003-01-16 | — | — | US | claimed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9771369-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| CN-103562342-B | Organic light emitting device and method of manufacturing the same | 株式会社LG化学 | 2017-02-15 | — | — | CN | disclosed |
| EP-1165085-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6184245-B1 | Cyclic ketone derivatives and their medical applications | TORAY INDUSTRIES INC. (JP) | 2001-02-06 | — | — | US | disclosed |
| WO-2000059509-A1 | PHTHALAZINE DERIVATIVES FOR TREATING INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2000-10-12 | — | — | WO | disclosed |
| US-6100292-A | Ketone derivatives and their medical applications | TORAY INDUSTRIES, INC. (JP) | 2000-08-08 | — | — | US | disclosed |
| EP-0980867-A1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-02-23 | — | — | EP | disclosed |
| EP-0962456-A1 | CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013718-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, KDR, FFAR2 | TAAR1 1071/4885L3MBTL1 2284/4885KDM4E 1959/4885 |
| US-20040142934-A1 | Phthalazine derivatives for treating inflammatory diseases | KDR, FLT1, TIE1 | TAAR1 1173/4885L3MBTL1 4604/4885KDM4E 2156/4885 |
| US-20050176711-A1 | Phthalazine derivatives for treating inflammatory diseases | FLT1, FLT4, KDR | TAAR1 746/4885L3MBTL1 1941/4885KDM4E 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.